Inflarx to start two Phase 2 izicopan trials in AAV in 2027
Inflarx says the first data from the trials are expected in 2028.
Related stories
Utkarsh Small Finance Bank Reports Q2 Net Loss of 698.5 Million Rupees
M impact | EQUITY | Nov 03, 2026, 02:35 PM UTC
Apple shares fall after Ternus warns of memory costs
Apple shares fell after Ternus warned about memory costs.
L impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
Clorox Shares Rise About 6% After Q1 Results Beat
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
TransAlta shares rise 7.7% as net earnings turn positive
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
IPG Photonics Reports Third-Quarter 2026 Revenue of $287.5 Million
Revenue rose 15% year over year and exceeded FactSet estimates of $283.3 million. Adjusted EPS was $0.61 versus consensus of $0.49. IPG guided to fourth-quarter revenue of $265 mil
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC
DigitalOcean Reports Q3 Revenue of $321 Million, Raises 2026 Outlook
Third-quarter revenue rose 40% year over year to $321 million; adjusted EPS was $0.45 versus FactSet consensus of $0.32. The company guided fourth-quarter revenue to $348 million–$
M impact | EQUITY | Nov 03, 2026, 02:34 PM UTC